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Preamble
It is becoming more apparent each day that despite a
strong national commitment to excellence in health care, the
resources and personnel are finite. It is, therefore, appropri-
ate that the medical profession examine the impact of
developing technology on the practice and cost of medical
care. Such analyses, carefully conducted, could potentially
have an impact on the cost of medical care without dimin-
ishing the effectiveness of that care.
To this end, the American College of Cardiology and the
American Heart Association in 1980 established a Task
Force on Assessment of Diagnostic and Therapeutic Cardio-
vascular Procedures with the following charge:
The Task Force of the American College of Cardiology and
the American Heart Association shall define the role of
specific noninvasive and invasive procedures in the diag-
nosis and management of cardiovascular disease.
The Task Force shall address, when appropriate, the contri-
bution, uniqueness, sensitivity, specificity, indications,
contraindications and cost-effectiveness of such specific
procedures.
The Task Force shall include a Chairman and six members,
three representatives from the American Heart Associa-
tion and three representatives from the American College
of Cardiology. The Task Force may select ad hoc mem-
bers as needed upon the approval of the Presidents ofboth
organizations. Recommendations of the Task Force are
forwarded to the President of each organization.
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The members of the Task Force are: George A. Beller,
MD, Roman W. DeSanctis, MD, Harold T. Dodge, MD,
J. Ward Kennedy, MD, T. Joseph Reeves, MD, Sylvan Lee
Weinberg, MD and Charles Fisch, MD, Chairman.
This document was reviewed by the officers and other
responsible individuals of the two organizations and re-
ceived final approval in October 1991. It is being published
simultaneously in Circulation and the Journal of the Amer-
ican College of Cardiology. The potential impact of this
document on the practice of cardiology and some of its
unavoidable shortcomings are clearly set out in the introduc-
tion.
Charles Fisch, MD, FACC
I. Introduction
A. Defining the Role of Electrocardiography in
Clinical Practice
Einthoven (l,2) published the first description of his
string galvanometer in 1901 and the first results of its
application in 1903. The first commercial string galvanome-
ter was manufactured by the Cambridge Instrument Com-
pany of London in 1908 (3). In the years since these major
milestones, electrocardiography has undergone significant
technical advances and has become the most widely em-
ployed technical procedure for evaluating cardiovascular
function. It remains an important keystone for the care of
patients with both cardiac and noncardiac diseases. It is
painless, without direct risk to the patient and is reproduc-
ible. Compared with many other procedures, it is relatively
inexpensive to perform.
The basic electrophysiologic principles underlying clini·
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cal electrocardiography are usually taught in physiology
courses in medical schools and some medical students learn
rudimentary electrocardiography during their clinical years
in medical school. However, most physicians who interpret
electrocardiograms (ECGs) become experienced and de-
velop skills in interpretation during residency or cardiovas-
cular fellowship training and subsequently in clinical prac-
tice. In recent years, computers have become an integral
part of some ECG systems. Although computer programs
can usually provide accurate information regarding the heart
rate, intervals and electrical axes, all computer ECG inter-
pretations, particularly interpretations of rhythm distur-
bances, ischemia or infarction, require careful overreading
by a physician qualified to interpret ECGs. Before an ECG
can have proper diagnostic accuracy and clinical usefulness,
a skilled physician is required to compare it with previous
tracings and, particularly, to integrate clinical data and
provide a differential diagnosis. No computer program for
ECG interpretation can replace the interpretation provided
by a skilled physician (4,5). An incorrect ECG diagnosis can
have significant undesirable medical and legal consequences.
In considering the appropriate use of electrocardiog-
raphy, the physician should examine the clinical question
being asked, the additional information to be derived and the
usefulness of the new information in establishing a diagnosis
or making a management decision. The unique role of the
responsible physician should always be kept in mind. Thus,
there are circumstances when the physician's judgment
transcends the specific recommendations of these (or other)
guidelines. For example, there may be instances when it is
very appropriate to obtain an ECG in a patient with an acute
illness even when no cardiac symptom, physical finding or
risk factor is present or when none of the commonly recog-
nized indications for an ECG are present (Class I or II
categories of this report). In other instances, an ECG may be
obtained as a baseline study before another procedure such
as an exercise test or a signal-averaged ECG is performed or
before the patient undergoes a high risk procedure or is
treated with some pharmacologic agents.
The ECG is the product of a unique technology that
provides a record of electrical activity of the heart and
information not readily obtained by other methods. It has
many uses, including the following: it may serve as an
independent marker of myocardial disease; it may reflect
electrophysiologic, anatomic, metabolic and hemodynamic
alterations; it may provide information that is essential for
the proper diagnosis and therapy of a variety of cardiac
disorders and it is without equal as a noninvasive method for
the diagnosis and treatment of arrhythmias. It is the proce-
dure of first choice in patients presenting with chest pain,
dizziness or syncope-symptoms that may be predictive of
sudden death or myocardial infarction. Electrocardiographic
abnormalities also may be the first indicators of life-
threatening side effects of drugs or of severe metabolic or
electrolyte disturbance and occasionally may be the only
sign of myocardial disease such as, for example, "asympto-
matic" myocardial infarction in the aged (6).
Consideration of sensitivity and specificity. Appropriate,
accurate use of the ECG requires an understanding and
appreciation of its sensitivity and specificity. The task of
achieving this understanding is somewhat more complex for
the ECG than for many other laboratory tests because the
ECG is composed of several waveforms, each of which has
its own sensitivity and specificity and each of which may be
influenced differently by a variety of pathologic and patho-
physiologic factors (6).
When one considers the sensitivity and specificity of the
ECG, it is important to recognize that the ECG is a record of
electrical activity. Consequently, diagnoses of structural
changes (myocardial infarction, hypertrophy) or pathophys-
iologic changes (electrolyte disturbance, effect of drugs) are
made by inference and are therefore subject to error. The
data that allow for a diagnosis by inference have been
derived from extensive studies correlating the ECG with a
variety of clinical, pathologic and experimental states (6).
It is also important to recognize that the same ECG
pattern may be recorded in patients with different structural
and pathophysiologic states. This explains the frequent low
specificity of the ECG for determining the etiology and
anatomy of cardiovascular disease (6). For example, the ST
segment and the T wave changes are generally the most
common and the most sensitive ECG abnormalities, but
these changes are at the same time the least specific (7,8).
Similarly, different etiologic factors and structural abnormal-
ities may result in an identical ECG pattern ofbundle branch
block.
It is apparent from these considerations that the sensitiv-
ity and specificity of the ECG depend to a large extent on the
specific clinical question being asked. Thus, the sensitivity
and specificity of the ECG for myocardial disorders vary
considerably depending on the cause of the disorder and on
the size and location of the pathologic process, whereas they
are consistently high for arrhythmias. The ECG is the only
practical, noninvasive method of recording and analyzing
abnormalities of cardiac rhythm.
This report is intended to provide guidelines rather than
standards. Furthermore, because it is impossible to consider
all clinical situations, the general principles underlying the
examples in these guidelines can be extended to other
specific cases by the responsible physician, utilizing his or
her best clinical judgment.
In this report the guidelines for indications for ECG study
are classified by patient group: 1) patients with known
cardiovascular disease or dysfunction; 2) patients who are
suspected of having, or who are at increased risk of devel-
oping, cardiovascular disease or dysfunction; and 3) patients
with no apparent or suspected heart disease or dysfunction.
Within each group of patients, guidelines for electrocardio-
graphy are classified as follows:
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Class I: Conditions for which or patients for whom
there is general agreement that electrocardio-
graphy is useful.
Class II: Conditions for which or patients for whom
electrocardiography is frequently used but
there is divergence of opinion with respect to
its usefulness.
Class III: Conditions for which or patients for whom
there is general agreement that electrocardiog-
raphy is of little or no usefulness.
B. Assumptions Underlying the
Committee Report
This report is based on the assumption that the ECG is
performed and interpreted in accordance with the guidelines
for optimal electrocardiography described in the American
College of Cardiology 10th Bethesda Conference report (9),
the guidelines for training described in the American College
of Cardiology 17th Bethesda Conference report on cardiol-
ogy training (10), the recommendations for standardization
of leads and specifications for instruments in electrocardiog-
raphy and vectorcardiography of the American Heart Asso-
ciation (11) and the recommendations for standardization
and specifications for automated electrocardiography of the
American Heart Association (12).
II. Definition of Terms
To ensure compatibility of data transfer among varying
sources of information pertaining to the ECG and to assure
the correct exchange of information among multiple sources
of information, the definitions of terms employed need to be
as precise as possible, The following definitions are used in
this document:
Electrocardiogram (ECG): Astandard 12-lead ECG, with
or without a rhythm strip or other special leads, that has
been interpreted by a physician qualified to interpret ECGs
and that has been made part of the patient's medical record.
An ECG that has been interpreted by a computer alone is not
recognized as a properly interpreted ECG. The term ECG
does not refer to continuous ambulatory electrocardiog-
raphy, monitor leads, rhythm strips, exercise testing, trans-
telephonic recordings, signal-averaging techniques with late
potentials or intracardiac electrograms. In most cases a
12-lead ECG is required for accurate interpretation of these
latter studies or is necessary to provide complementary
information. In children and selected adults, it may be
necessary to record additional leads.
Cardiovascular disease: Disease in which the heart,
pericardium or blood vessels are directly or indirectly in-
volved. Examples of direct involvement include coronary
artery disease, cardiomyopathy, valvular disease, congenital
heart disease, arrhythmias and conduction disturbances.
Examples of indirect involvement or conditions with co-
morbidity that could affect the heart include systemic hyper-
tension, pulmonary hypertension and serum electrolyte ab-
normalities. The conditions may be permanent or transient,
slowly or rapidly progressive or nonprogressive, life-
threatening or usually associated with a good prognosis.
These descriptors and the presence or absence of new or
changing symptoms, physical signs or laboratory findings are
important in determining the frequency of repeat 12-lead
ECGs.
Cardiovascular dysfunction: Dysfunction with or without
documented underlying organic heart disease. The dysfunc-
tion may indicate either inappropriate mechanical perfor-
mance or electrical dysfunction evidenced by arrhythmias or
conduction abnormalities.
Response to therapy: Improvement or worsening of the
cardiovascular disease or dysfunction in response to treat-
ment directed either to the underlying condition (for exam-
ple, valve replacement, antiarrhythmic drug) or to the indi-
rectly responsible cause (for example, antihypertensive
therapy). The therapy may be invasive (for example, coro-
nary angioplasty or cardiac surgery) or pharmacologic.
Follow-up: The use of serial ECGs to aid in the assess-
ment of the severity and progression of the underlying
cardiovascular disease or dysfunction. The interval between
ECGs should be a medical judgment made by the responsible
physician after evaluation of many factors. These include
what is known about the natural history of the underlying
condition; the severity of the condition at the time of the
initial or the most recent evaluation; the presence of any
change in symptoms, physical signs or laboratory findings or
changes in the interval growth or maturation that suggest a
change in the cardiovascular condition or growth of a child.
Some examples of specific symptoms include syncope or
near-syncope, palpitation, an unexplained change in the
usual pattern of anginal pain, new or worsening dyspnea, a
recent cerebrovascular or other embolic event, extreme
unexplained fatigue, weakness or prostration.
Before surgery: refers to an ECG performed before
surgery for the purpose of evaluating cardiac risk.
III. Introduction to Indications for
Electrocardiography in Different
Patient Groups
The indications that follow for the use of electrocardiog-
raphy have been classified by the following three patient
groups:
Group IV: Patients with known cardiovascular disease
or dysfunction.
Group V: Patients who are suspected of having, or
who are at increased risk of developing,
cardiovascular disease or dysfunction.
Group VI: Patients with no apparent or suspected heart
disease or dysfunction.
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Within each group, indications are separated according to
the following categories:
A. Baseline or initial evaluation.
B. Response to therapy.
C. Follow-up.
D. Before surgery.
It must be kept in mind that for any individual patient both
the group and the category of indication may change with
time.
IV. Indications for Electrocardiography in
Patients With Known Cardiovascular Disease
or Dysfunction
A. Baseline or Initial Evaluation
1. General considerations
The ECG is accepted as a useful and important baseline
test in all patients with known cardiovascular disease, dys-
function or arrhythmia during the initial evaluation. In some
instances more than one ECG is required during the initial
evaluation if the underlying condition is evolving rapidly (as
in acute myocardial infarction) or is intermittent or transient
(as with anginal attacks or certain arrhythmias and conduc-
tion defects). A baseline ECG may disclose useful informa-
tion regarding diagnosis and prognosis and may permit
rational decisions regarding management, including risk of
medical and surgical intervention. A baseline ECG in pa-
tients with known heart disease or dysfunction gives useful
information regarding the presence or absence of arrhyth-
mias, conduction defects, chamber enlargement, myocardial
hypertrophy, myocardial ischemia, myocardial necrosis,
pericardial inflammation and electrolyte disturbance. It is
especially noteworthy that in such patients, for certain
conditions (for example, arrhythmias, conduction defects,
myocardial infarction) the baseline ECG may give instanta-
neous information that is not available with other tests.
2. Classification of indications for electrocardiography for
baseline or initial evaluation of patients with known cardio-
vascular disease or dysfunction
Class I
a. In patients with known cardiovascular disease or
dysfunction.
Class II
None.
Class III
None.
B. Response to Therapy
1. General considerations
After the initial evaluation, subsequent ECGs may be
indicated to evaluate short-term and long-term responses to
therapy. Conditions in which serial ECGs may be useful in
this regard include, but are not limited to, the following:
regression or progression of chamber enlargement or myo-
cardial hypertrophy, resolution or alterations of arrhythmias
or conduction disturbances, pacemaker function, acute myo-
cardial infarction or ischemia, electrolyte disturbances, peri-
carditis, endocarditis, myocarditis, acquired immune defi-
ciency syndrome (AIDS), transplant rejection, infiltrative
cardiomyopathies, therapy with antineoplastic agents and
other conditions known to produce ECG changes. When
patients with these conditions receive therapy that is not
expected to influence the ECG findings, they do not usually
require a repeat ECG unless it is indicated by the appearance
of new symptoms or findings. In general, the frequency of
repeat ECGs is best determined by the specific condition and
left to the judgment of the patient's physician. Repeat or
serial ECGs are often indicated until the patient's disease
process and ECG response to therapy have stabilized. In
different situations this may require multiple ECG record-
ings over a period of minutes, hours, days, weeks or years.
Although continuous ECG rhythm monitoring may be avail-
able in some clinical settings, the diagnostic information
obtained in this manner is often less informative than that
obtained from a full 12-lead ECG and may be inadequate in
a given situation.
2. Selected examples of frequently encountered problems
In patients with acute ischemia, the ECG may be used to
assess reversal or progression of this condition. Serial ECGs
are therefore appropriately used to monitor responses to
thrombolytic or anti-ischemic therapy or to verify spontane-
ous recovery. They may be used for similar reasons in
patients with myocarditis, pericarditis or endocarditis.
In patients who have undergone coronary angioplasty or
other intracardiac invasive procedures or electrophysiologic
ablative procedures, serial ECGs are warranted until the
condition is stable and again shortly before hospital dis-
charge in all patients, including those with uncomplicated
procedures.
In patients in whom antiarrhythmic drug therapy is
initiated, serial ECGs may be useful to assess conversion to
normal sinus rhythm, changing rhythm, QRS duration, pro-
longation of the QT interval or proarrhythmia. Patients who
are being monitored may require a 12-lead ECG if one or
more of these changes is suspected, particularly alterations
in the PR, QRS and QT intervals and relevant morphologic
changes.
Patients receiving drug therapy with potential cardiac
effects: Many drugs that are used for either cardiovascular
conditions or noncardiovascular conditions may produce
cardiac effects that may be detected by the ECG even if their
primary pharmacologic action is not best monitored by
electrocardiography. Electrocardiograms may therefore be
indicated before and during therapy with such drugs to
protect against adverse reactions. Some commonly used
drugs known to produce significant ECG changes are psy-
chotropic agents, such as phenothiazines, tricyclic and tet-
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racyclic antidepressants and lithium; anti-infective agents,
such as erythromycin or pentamidine; antihypertensive
agents, such as diuretic drugs, angiotensin-converting en-
zyme inhibitors, calcium channel and beta-adrenergic recep-
tor blocking agents; antineoplastic agents and anti-heart
failure agents, such as digitalis, dopamine and dobutamine;
similarly, many other drugs may produce changes detectable
by the ECG. Electrocardiographic recordings are appropri-
ate after initiation of drug therapy, after changes in therapy
and after addition to the regimen of other drugs that may
interact and have cardiac effects.
Patients undergoing electrical or pharmacologic cardio-
version of ventricular tachycardia, supraventricular tachy-
cardia, atrialfibrillation or atrialflutter should have an ECG
just before and immediately after the procedure and before
hospital discharge.
Pacemaker malfunction or suboptimal programming may
be detected by serial ECGs even in the absence of symp-
toms. A 12-lead ECG is indicated soon after pacemaker
insertion or revision, whenever a pacemaker malfunction is
suspected, after lead threshold maturation and at periodic
intervals throughout the lifetime of the patient and the pacing
system. More frequent ECGs are usually indicated with
atrial or dual-chamber pacing systems since atrial lead
malfunction may not be easily detectable otherwise. These
indications also apply to antitachycardia and antifibrillatory
devices that have pacemaker capability.
In patients after cardiac surgery or extensive pulmonary
surgery including transplantation, serial ECGs are recom-
mended until the condition is stable and shortly before the
patient's discharge.
3. Classification of indications for electrocardiography to
assess the response to therapy of patients with known cardio-
vascular disease or dysfunction
Class I
a. In patients in whom prescribed therapy is known to
produce ECG changes that correlate with therapeutic
responses or progression of disease.
b. In patients in whom prescribed therapy may produce
adverse effects that may be predicted from or detected
by ECG changes.
Class II
None.
Class III
a. In patients receiving pharmacologic or nonpharmaco-
logic therapy not known to produce ECG changes or
to affect conditions that may be associated with such
changes.
C. Follow-Up
1. General considerations
Many cardiovascular diseases undergo progressive wors-
ening with time despite therapy, with or without acute
exacerbations, and this progression may be evaluated by
periodic (for example, yearly) ECGs. In an individual patient
the appropriate interval depends on the known natural
history of the disease, the age of the patient, the effective-
ness of therapy and the severity of the disease when the
patient was last evaluated. In general, the indications for
follow-up ECGs and their frequency should be determined
by the responsible physician largely on the basis of changes
in symptoms, physical signs, growth or maturation of infants
or children, or laboratory findings.
2. Specific examples of frequently encountered symptoms or
findings
Examples of symptoms that warrant a repeat ECG in-
clude the following:
Syncope and near-syncope
Unexplained change in the usual pattern of angina pecto-
ris
Chest pain
New or worsening dyspnea
Extreme and unexplained fatigue, weakness and prostra-
tion
Palpitation
Examples offindings that warrant a repeat ECG include
the following:
New signs of congestive heart failure
A new organic murmur or pericardial friction rub
New findings suggesting pulmonary hypertension
Accelerating or poorly controlled systemic arterial hyper-
tension
Evidence of a recent cerebrovascular accident
Unexplained fever in patients with known valvular dis-
ease
New onset of cardiac arrhythmia or inappropriate heart
rate
Examples of diseases or conditions in which ECG
changes may often reflect progression or improvement of
underlying cardiovascular disease without the appearance
of new symptoms or signs include the following:
Valvular or congenital heart disease
Convalescence after acute myocardial infarction, cardiac
surgery or coronary angioplasty
Chronic ischemic heart disease, Kawasaki disease or
anomalous origin or course of proximal coronary
artery
Moderate or severe systemic arterial hypertension
Pericarditis, myocarditis or endocarditis
Conduction abnormalities
Long QT syndrome, pre-excitation syndromes
Implanted pacemakers or antitachycardia devices
Co-morbidity such as renal failure, diabetic acidosis,
hypothermia or electrolyte abnormalities
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3. Classification of indications for electrocardiography in the
follow-up evaluation of patients with known cardiovascular
disease or dysfunction
Class I
a. Patients with a change in symptoms, signs or relevant
laboratory findings.
b. Patients with an implanted pacemaker or antitachycar-
dia device.
c. Patients with the preceding conditions, even in the
absence of new symptoms or signs, after an interval of
time appropriate for the condition or disease, except
as described in Class III.
Class II
None.
Class III
a. In adult patients whose cardiovascular condition is
usually benign and unlikely to progress, ECGs are not
indicated at follow-up visits unless changes in clinical
status occur. Such patients include those with asymp-
tomatic mild mitral valve prolapse, minimal to mild
systemic arterial hypertension or premature contrac-
tions in the absence of organic heart disease.
b. In adult patients with chronic stable heart disease seen
at frequent intervals (i.e., ::54 months) and who have
no new or unexplained symptoms, physical or labora-
tory findings, follow-up ECGs at each visit are not
indicated. Such patients include those with systemic
arterial hypertension, chronic coronary artery disease,
valvular heart disease, cardiomyopathy or lone atrial
fibrillation.
D. Before Surgery
1. General considerations
A recent preoperative ECG is recommended in patients
with known cardiovascular disease undergoing cardiac or
noncardiac surgery. These patients may have an increased
risk for perioperative cardiovascular complications.
2. Classification of indications for electrocardiography for
preoperative evaluations of patients with known cardiovascu-
lar disease or dysfunction
Class I
a. All patients with known cardiovascular disease or
dysfunction except as noted under Classes II and III.
Class II
a. Patients with hemodynamically insignificant congeni-
tal or acquired heart disease, minimal to mild systemic
arterial hypertension or infrequent premature com-
plexes in the absence of organic heart disease.
Class III
None.
V. Indications for Electrocardiography in
Patients Who Are Suspected of Having or
Who Are at Increased High Risk of
Developing Cardiovascular Disease
or Dysfunction
A. Baseline or Initial Evaluation
1. General considerations
The recording of an ECG is an integral and useful part of
the initial evaluation and the follow-up of patients with
suspected cardiac disease. A cardiac abnormality may be
suspected on the basis of a patient's symptoms, abnormal
physical findings, previous abnormal ECGs, abnormal radio-
graphic or echocardiographic findings or other abnormal
laboratory studies or conditions commonly associated with
or increasing the risk of development of cardiac disease or
dysfunction. Common symptoms include chest pain, dysp-
nea, palpitation, syncope, edema, cough, hemoptysis or
intermittent claudication. Examples of abnormal physical
findings are hypertension, hypotension, cardiomegaly, heart
murmur, pericardial friction rub, inappropriate heart rate,
irregular heart rhythm, gallop rhythm, elevated venous
pressure, dependent edema, hepatomegaly, evidence of pul-
monary congestion, new cerebrovascular event, cyanosis,
nonfebrile seizures, congenital deafness, chest trauma, ca-
rotid, cranial or abdominal bruit or evidence of increased
intracranial pressure. Abnormal laboratory findings include
anemia, electrolyte abnormalities, lipid abnormalities and
azotemia. Examples of conditions that are associated with,
or that increase the risk of, cardiac disease include advanced
age, diabetes mellitus, tobacco use, hyperlipidemia, pulmo-
nary disease, peripheral vascular disease, thyroid disease,
muscular dystrophies, collagen vascular disease, sarcoido-
sis, amyloidosis, drug abuse, chest trauma, anorexia ner-
vosa, dysmorphic syndromes or a family history of coronary
artery disease, sudden cardiac death, pre-excitation, long
QT syndrome, hypertrophic cardiomyopathy or other
heredofamilial diseases with a significant incidence of car-
diac disease.
The ECG is an important component of the initial assess-
ment of many patients entering the emergency room. This is
especially true for middle-aged or elderly persons, for those
possibly exposed to inhaled or ingested toxins and for
patients with altered mental status who cannot contribute a
reliable history.
2. Classification of indications for electrocardiography for the
baseline or initial evaluation or diagnosis of patients with
suspected, or at increased risk of developing, cardiac abnor-
malities or dysfunction
Class I
a. Patients with suspected cardiac disease or dysfunc-
tion, as described under General considerations.
b. Patients at increased risk for the development of
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cardiac disease, as described under General consider-
ations.
c. Patients who may have used cocaine, amphetamines
or other illicit drugs known to have cardiac effects.
d. Patients who may have received an overdose of a drug
known to have cardiac effects.
Class II
None.
Class III
None.
B. Response to Therapy
Classification of indications for electrocardiography to assess
the response to therapy of patients with suspected, or at
increased risk of developing, cardiovascular disease or dys-
function
Class I
a. To assess therapy with cardioactive drugs in patients
with suspected cardiac disease. (For example, the use
of beta-blocker drugs in patients with palpitation,
tremor or migraine headache.)
b. To assess the response to the administration of any
agent known to result in cardiac abnormalities or ECG
abnormalities. (For example, antineoplastic drugs,
lithium, tranquilizers and anticonvulsant and antide-
pressant agents.)
Class II
a. To assess the response to administration of any agent
known to alter serum electrolyte concentrations. (Di-
uretic drugs in hypertensive patients are one example.
An ECG may be indicated when the potassium or
magnesium concentration is suspected or known to be
altered into or near the abnormal range.)
Class III
a. To assess the response to administration of agents
known not to influence cardiac structure or function.
C. Follow-Up
Classification of indications for electrocardiography in the
follow-up evaluation of patients with suspected, or at increased
risk of developing, cardiac disease or dysfunction
Class I
a. The presence of any change in clinical status or
laboratory findings suggesting the interval develop-
ment of cardiac disease or dysfunction.
b. The periodic follow-up (for example, every I to 5
years) of patients known to be at increased risk for the
development of cardiac disease. More frequent follow-
up may be appropriate in children <2 years of age.
c. The follow-up of patients after the resolution of chest
pain.
Class II
None.
Class III
a. Follow-up ECGs more often than once yearly are not
indicated in patients who remain clinically stable, who
are not at increased risk for the development of
cardiac disease and who have not been demonstrated
to have cardiac disease with previous studies.
D. Before Surgery
Classification of indications for electrocardiography in the
preoperative evaluation of patients with suspected, or at
increased risk of developing, cardiac disease or dysfunction
Class I
a. As part of the preoperative evaluation of any patient
with suspected, or at increased risk of developing,
cardiac disease or dysfunction, as discussed under
General considerations.
Class II
None.
Class III
None.
VI. Indications for Electrocardiography in
Patients With No Apparent or Suspected
Heart Disease or Dysfunction
General Considerations
The ECG has been a traditional and fundamental part of
screening programs for the detection of heart disease. Many
studies have established that apparently normal persons may
have a significant prevalence of normal variations and ab-
normalities in their ECG (13-23). Other studies have found a
significant percentage of angiographic abnormalities in
asymptomatic aircrewmen with ECG abnormalities (24); and
in another study (19) approximately 8% of asymptomatic
aircrewmen with minor ST-T wave changes at rest had
significant coronary artery disease. In general, the frequency
of ECG abnormalities increases exponentially with age.
Thus, there is a prevalence of approximately 10% of such
abnormalities by about age 35 years and a 25% prevalence by
about age 60 years, using pooled data combining a variety of
ECG findings in both men and women (22,25). It is also
known that a significant proportion of myocardial infarctions
in men over age 30 years and in women over age 40 years are
asymptomatic but can be diagnosed by ECG and are asso-
ciated with a prognosis similar to that of patients with
symptomatic myocardial infarction (26-30). Unfortunately,
there are no adequate studies of patients discovered to have
an unrecognized myocardial infarction of indeterminate age
on a routine preoperative ECG (25).
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Because of the preceding and other considerations, dif-
ferent groups have recommended either that a baseline ECG
be obtained in all adults and a routine annual ECG be
obtained in patients at high risk of having heart disease (9) or
that a baseline ECG be obtained at age 20 years and repeated
at ages 40 and 60 years (31). Unfortunately, no large, statis-
tically valid, prospective long-term studies have been con-
ducted to determine the cost-effectiveness of such recom-
mendations. A recent review (32) of the available studies
concluded that data were insufficient to support performing a
routine baseline ECG in young healthy persons without
evidence of cardiac disease or cardiovascular risk factors. In
presumably normal persons who are known to have had a
normal ECG in the past, the likelihood is low that a repeat
ECG will be specifically helpful in the absence of a change in
general health status or a new onset of cardiac symptoms.
Because the value of a screening ECG has not been com-
pletely identified, its proper use is best determined by the
responsible physician for an individual patient. Additional
prospective studies on the use of baseline or screening ECGs
are needed.
The cost-effectiveness of ECGs obtained routinely for
hospital admissions or before surgery has also come under
scrutiny (25,33), although this practice has been and is
recommended in selected patient groups (21,22,23). The
cost-effectiveness of the preoperative ECG in apparently
healthy persons has also not been adequately evaluated by a
large, prospective study.
It has been recognized (34) that more stringent examina-
tion standards must be applied to persons in high risk
occupations and to those whose performance affects the
safety of others.
The baseline or initial evaluation described below may be
a routine physical examination, pre-employment examina-
tion, insurance examination, school health examination,
examination preceding the start of a weight reduction or
exercise program, routine hospital admission or any other
cardiac screening program in which the patient has previ-
ously not been known or suspected to have heart disease or
an increased risk of having heart disease.
When persons in this category (patients with no apparent
or suspected heart disease or dysfunction) develop or are
found to have symptoms, signs, risk factors or ECG or other
laboratory findings that suggest an increased risk of cardio-
vascular disease or dysfunction, they then belong in the
preceding group of patients.
A. Baseline or Initial Evaluation
Classification of indications for electrocardiography for base-
line or initial evaluation of patients with no apparent heart
disease or dysfunction
Class I
a. To evaluate persons >40 years of age undergoing
physical examination.
b. To evaluate patients before administration of pharma-
cologic agents that are known to have a high incidence
of cardiovascular effects (for example, chemotherapy
of malignancies).
c. To evaluate persons before exercise stress testing.
d. To evaluate patients of any age who are in special
occupations that require very high cardiovascular per-
formance (for example, fire fighters, police officers,
astronauts) or whose cardiovascular performance is
linked to public safety (for example, pilots, air traffic
controllers, critical process operators, bus or truck
drivers and railroad engineers).
Class II
a. To evaluate competitive athletes.
Class III
a. Routine screening or baseline ECGs in asymptomatic
persons <40 years of age with no risk factors, except
as specified under Class I or II.
B. Response to Therapy
Classification of indications for electrocardiography to assess
the response to therapy of patients with no apparent heart
disease or dysfunction
Class I
a. To evaluate patients in whom prescribed therapy (for
example, doxorubicin) is known to produce cardiovas-
cular effects.
Class II
None.
Class III
a. To assess treatment that is known not to produce any
cardiovascular effects.
C. Follow-Up
Classification of indications for electrocardiography in the
follow-up evaluation of patients with no apparent heart disease
or dysfunction
Class I
a. To evaluate asymptomatic persons >40 years of age.
Class II
a. None
Class III
a. To evaluate asymptomatic adults who have had no
interval change in symptoms, signs or risk factors and
who have had a normal ECG within the recent past.
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D. Before Surgery
Classification of indications for electrocardiography for the
preoperative evaluation of patients with no apparent heart
disease or dysfunction
Class I
a Patients >40 years old.
b. Patients being evaluated as a donor for heart trans-
plantation or as a recipient of a noncardiopulmonary
transplant.
Class II
a. Patients 30 to 40 years of age.
Class III
a. Patients <30 years old with no risk factors for coro-
nary artery disease.
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